SUPPLEMENTARY INFORMATION (CORRECTIVE INFORMATION) TO THE ANNUAL REPORT 2024 AND THE INTERIM REPORT FOR H1 2025 Hørsholm 26 February 2026 Company announcement #1 Pharma Equity Group A/S (the “Company”) hereby publishes the effects of a correction to the Company’s annual report for 2024 as well as the interim report for the first half of 2025. TABLE OF CONTENTS Background to the corrective informationManagement’s statementIndependent auditor’s reportCorrection to the consolidated financial statements for 202 ...

Core Viewpoint - Vir Biotechnology, Inc. has announced the pricing of its public offering of common stock, aiming to raise $150 million through the sale of 17,647,058 shares at $8.50 per share, with a potential additional option for underwriters to purchase up to 2,647,058 shares [1] Group 1: Offering Details - The public offering consists of 17,647,058 shares priced at $8.50 each, expected to generate gross proceeds of $150 million before expenses [1] - Underwriters have a 30-day option to purchase an additional 2,647,058 shares at the public offering price [1] - The offering is set to close on February 27, 2026, pending customary closing conditions [1] Group 2: Underwriters and Registration - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering [1] - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on November 3, 2023 [1] Group 3: Company Overview - Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer [1] - The company's clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers targeting solid tumors [1]

L’Oréal SA played a key role in the ouster last week of Sanofi SA Chief Executive Officer Paul Hudson and the choice of his successor, in what was a major corporate shakeup for the French pharmaceutical company. https://t.co/EIU9A7PMZW ...

Core Insights - EnWave Corporation reported consolidated interim financial results for Q1 2026, showing significant revenue growth and improvements in gross margin compared to the previous year [1][4]. Financial Performance - Revenues for Q1 2026 reached CAD 1,600,000, an increase of 36% from CAD 1,177,000 in Q1 2025, attributed to large-scale machine sales and increased royalties [2][4]. - Direct costs rose to CAD 1,006,000, up 20% from CAD 837,000 in the prior year [2]. - Gross margin improved to CAD 594,000, representing a 75% increase from CAD 340,000, with a gross margin percentage of 37% compared to 29% in Q1 2025 [2][4]. - Operating expenses totaled CAD 1,468,000, a 16% increase from CAD 1,268,000, driven by higher sales personnel and other costs [2][4]. - The net loss from continuing operations was CAD 1,108,000, an 18% increase from CAD 938,000 in the previous year [2][4]. - Adjusted EBITDA loss was CAD 585,000, showing an improvement of CAD 50,000 from CAD 635,000 in Q1 2025 [2][4]. Revenue Breakdown - Base royalties for Q1 2026 were CAD 500,000, an 18% increase from CAD 425,000 in the prior year [4]. - Total royalty revenue for Q1 2026 was CAD 627,000, a 12% increase from CAD 559,000 in Q1 2025, driven by more royalty partners and increased product sales [4]. Corporate Developments - EnWave signed several Commercial License Agreements (CLAs) with partners, including Gowen Gumlu Grower's Association in Australia and Shinyway International Limited in New Zealand, indicating expansion in its market presence [10][11]. - The company has developed a robust intellectual property portfolio and continues to innovate in vacuum microwave dehydration technology, enhancing its competitive edge in the food, pharmaceutical, and cannabis industries [8][9].

Group 1 - Daiichi Sankyo has appointed John Tsai, MD as the new Global Head of R&D, effective April 1, 2026, succeeding Ken Takeshita, MD [1] - Dr. Tsai brings over 25 years of experience in driving innovation and leadership in the biotech and pharmaceutical sectors, previously serving at Syncona Investment Management and Novartis AG [1] - The company aims to leverage Dr. Tsai's expertise to enhance its R&D pipeline and accelerate the development of new medicines [1] Group 2 - Daiichi Sankyo has established a new research institute in San Diego, marking its third research facility outside Japan, following locations in Boston and Munich [1] - The company emphasizes its commitment to deepening relationships in key scientific hubs to foster innovation in healthcare [1]

Core Viewpoint - Conestoga Capital Advisors' fourth-quarter 2025 investor letter indicates that while US equities had solid returns in 2025, the market experienced significant volatility and leadership shifts, with the Small Cap Strategy underperforming the Russell 2000 Growth Index [1]. Company Overview - Stevanato Group S.p.A. (NYSE:STVN) is a global provider of high-performance drug containment and delivery solutions for the pharmaceutical industry [3]. - The company has a market capitalization of $4.431 billion [2]. Financial Performance - In Q4 2025, Stevanato Group S.p.A. stock closed at $16.23 per share, with a one-month return of -15.29% and a 12-month return of -20.71% [2]. - The company's engineering segment reported a 20% decline in revenue, which, despite representing only 15% of total revenue, has negatively impacted overall results [3]. - In Q3 2025, Stevanato Group S.p.A.'s revenue grew 9% year-over-year to $303.2 million [4]. Market Concerns - Investor concerns have increased regarding the potential impact of FDA approval and the introduction of oral GLP-1 therapies, creating near-term uncertainty for Stevanato Group S.p.A. due to its focus on injectable drug delivery [3]. - The stock is not among the 30 most popular stocks among hedge funds, with 13 hedge fund portfolios holding it at the end of Q3 2025, up from 8 in the previous quarter [4]. Investment Perspective - While acknowledging the potential of Stevanato Group S.p.A. as an investment, the company believes that certain AI stocks present greater upside potential and carry less downside risk [4].

Core Viewpoint - NetraMark Holdings Inc. successfully closed the second tranche of its non-brokered private placement, raising a total of $3.5 million through the issuance of 3.5 million units at $1.00 per unit, with plans to use the proceeds for working capital and general corporate purposes [1][4]. Group 1: Private Placement Details - The second tranche involved the issuance of 390,000 units at a price of $1.00 per unit, resulting in gross proceeds of $390,000 [1]. - Each unit consists of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $1.35 for two years [2]. - The total number of common shares outstanding after the second tranche is 92,223,699 [4]. Group 2: Regulatory and Insider Participation - The securities issued are subject to a four-month hold period, expiring on June 19, 2026, in accordance with Canadian securities laws [3]. - An insider participated in the second tranche, subscribing for 232,500 units, which is classified as a related party transaction [5]. - The company is exempt from formal valuation and minority shareholder approval requirements due to the transaction's size relative to its market capitalization [5]. Group 3: Company Overview and Technology - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a unique topology-based algorithm to analyze patient data [8][9]. - The company's technology allows for the segmentation of small datasets into explainable and unexplainable subsets, enhancing the accuracy of clinical trial insights [7].

Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Feb 19, 2026 6:30 AM Eastern Standard Time# Stevanato Group to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 4, 2026Share---PIOMBINO DESE, Italy--([BUSINESS WIRE])-- [Stevanato Group S.p.A.](NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issu ...

Group 1: Healthcare Industry Overview - Healthcare industry stocks serve as effective hedges against technology and growth stocks, performing well when larger stock markets do not [1] - The performance of stocks varies by sub-industry, with some pharmaceutical and biotech stocks behaving more like growth stocks [1] Group 2: Novo Nordisk - Novo Nordisk is a leading global pharmaceutical company specializing in GLP-1 drugs for weight loss and diabetes management, alongside Eli Lilly [6] - In fiscal 2025, sales for diabetes and obesity care drugs increased by 7%, with obesity care drugs seeing a 26% gain; sales growth for 2026 is projected between 5% to 13% [7] - The GLP-1 market is expected to grow to $254 billion by 2034, representing a compound annual growth rate of 17%, positioning Novo Nordisk for long-term benefits [7] - The stock is currently trading at a low valuation of 13 times earnings, priced at $49 per share, making it an attractive investment option [8] Group 3: AbbVie - AbbVie, a spinoff from Abbott Labs, has demonstrated strong defensive characteristics, rising 24% during the 2022 bear market while the S&P 500 fell by 18% [9] - AbbVie has consistently increased its dividend for 13 years since its separation from Abbott, currently offering a high yield of 3.1% [9]

Core Insights - Amazon Pharmacy will expand its Same-Day prescription delivery service to nearly 4,500 U.S. cities and towns by the end of 2026, adding approximately 2,000 new communities this year [1] - The expansion aims to provide fast and reliable medication delivery to millions of customers, particularly in states like Idaho and Massachusetts, where access to pharmacy services has been historically limited [1] Delivery Speed Improvements - In 2025, Amazon Pharmacy recorded significant delivery speed improvements, utilizing various transportation methods including e-bikes in urban areas and ferries in remote locations [1] - Customers in Los Angeles were able to pick up medications within minutes using Amazon Pharmacy Kiosks located in primary care offices, facilitating immediate treatment [1] Accessibility and Support Features - Amazon Pharmacy introduced a caregiver support feature in 2025 to assist families in managing medications for loved ones and expanded its $5-per-month RxPass prescription savings program to Prime members in 48 states [1] - The service also includes 24/7 access to licensed pharmacists and automatic refills, addressing the needs of customers in underserved areas [1] Savings and Pricing Transparency - In 2025, Amazon Pharmacy helped customers save over $150 million by applying eligible manufacturer-sponsored coupons, with significant savings on insulin and GLP-1 medications [1] - Prime members can save up to 80% on generic medications and 40% on brand-name medications through Prime Rx, with additional access to over 50 commonly prescribed medications via the RxPass program [1] Overall Strategy - Amazon Pharmacy is focused on redefining customer expectations in pharmacy care by combining pharmacy expertise with a robust logistics network to enhance accessibility, affordability, and convenience [1]